Epizyme, Inc. (NASDAQ:EPZM) Q2 2020 Earnings Conference Call - Final Transcript

Aug 04, 2020 • 08:30 am ET


Epizyme, Inc. (NASDAQ:EPZM) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Hello, and welcome to Epizyme's Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Epizyme's request.

I would now like to turn the call over to Alicia Davis. You may begin.

Alicia Davis

Thank you and good morning. This morning, we issued a press release, outlining recent progress in our second quarter 2020 financial results, which can be found at epizyme.com.

On the call with me is Rob Bazemore, CEO; Matt Ros, Chief Strategy and Business Officer; and Paolo Tombesi, Chief Financial Officer. Dr. Shefali Agarwal, Chief Medical Officer will join us for the Q&A session.

Today's discussion will include forward-looking statements related to Epizyme's current plans and expectations, which are subject to certain risks and uncertainties. Actual results may differ materially due to various important factors, including those described in the Risk Factors section of our most recent Forms 10-Q, 10-K, and other SEC filings. These forward-looking statements represent our views as of the call and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.

Now, let me turn the call over to Rob. Rob?

Robert Bazemore

Thank you, Alicia, and thank you all for joining us today. 2020 has been a landmark year for Epizyme, now an established commercial enterprise, marketing TAZVERIK in the United States as a standalone company for both solid tumor and hematological cancer indications.

Just six months into the year, we had delivered on the number of core objectives and complex milestones to bring the first EZH2 inhibitor to the market. With back-to-back FDA approvals for TAZVERIK, we recognized the special place we stand in our industry. The opportunity to provide patients and physicians with a generally well-tolerated and effective treatment for diseases where new options were needed is directly in line with our mission as the Company. TAZVERIK is approved in the US for the treatment of patients with metastatic or locally advanced epithelioid sarcoma, and for patients with relapsed or refractory follicular lymphoma, irrespective of their EZH2 mutational status. ES is a rare and aggressive solid tumor cancer with a high mortality rate that had no FDA indicated treatments prior to TAZVERIK's approval. FL is also an incurable cancer today, with a high rate of relapsed, frequently causing patients to progress through many lines of treatment over the course of their disease.

TAZVERIK is performing well in the market. While launching amidst COVID-19 is less than ideal, the initiatives that we put in place for ES have proven very helpful as we launched TAZVERIK in FL. The commercial progress made has demonstrated, by not just the sales we've achieved in the rare ES patient population, but is how our commercial operations are executing across many important dimensions. Our commercial team is adapting their efforts to stay engaged with our customers, based on how they want to be communicated with, and the uptake, interest and enthusiasm for TAZVERIK in both ES and FL among academic and community physicians has